79 related articles for article (PubMed ID: 16965682)
21. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
Teramoto K; Asada Y; Ozaki Y; Suzumura Y; Nakano Y; Sawai S; Tezuka N; Inoue S; Fujino S
Cancer Chemother Pharmacol; 2012 Oct; 70(4):531-7. PubMed ID: 22864949
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
[TBL] [Abstract][Full Text] [Related]
24. [Cisplatin-based chronotherapy for advanced none-small cell lung cancer: a randomized controlled study].
Li J; Ji M; Zhu LN
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):43-4. PubMed ID: 23648299
[No Abstract] [Full Text] [Related]
25. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H;
J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II study.
Firvida JL; Amenedo M; Rodríguez R; González A; Salgado M; Ramos M; Losada G
Invest New Drugs; 2004 Nov; 22(4):481-7. PubMed ID: 15292719
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer].
Gu LP; Shen SP; Chen ZW
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):939-42. PubMed ID: 21223805
[TBL] [Abstract][Full Text] [Related]
29. [Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer].
Wang YJ; Wu Q; Su FX; Zhou LZ; Ye ZB; Yang JQ; Ren H; Zhang J; Ding G; Fu Q; Wang N
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):541-4. PubMed ID: 19062725
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
Lin CM; Chen CH; Chang JW; Tsao TC
Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
32. [A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer].
Gao Y; Shi ZQ; Cao CW; Zhu CL; Guo J
Ai Zheng; 2005 Aug; 24(8):985-9. PubMed ID: 16086878
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
[TBL] [Abstract][Full Text] [Related]
35. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
Chemotherapy; 2005 May; 51(2-3):120-5. PubMed ID: 15886471
[TBL] [Abstract][Full Text] [Related]
37. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
[TBL] [Abstract][Full Text] [Related]
38. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
39. Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Yoh K; Kubota K; Ohmatsu H; Goto K; Niho S; Ohe Y
Anticancer Res; 2012 Sep; 32(9):4131-5. PubMed ID: 22993373
[TBL] [Abstract][Full Text] [Related]
40. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
